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ABSTRACT
 
Objective:
 
To assess the impact of risk management
activities on patient risk of glucocorticoid-induced
osteoporosis.
 
Methods:
 
Ninety-six adult patients taking chronic gluco-
corticoid therapy in 15 community pharmacies. Patients
in the control group received usual and customary care.
Patients in the treatment pharmacies received education
and an educational pamphlet about the risks of glucocor-
ticoid-induced osteoporosis. In addition, the treatment
group pharmacists monitored the patients’ drug therapy,
to identify and address drug-related problems. Data
including the glucocorticoid taken by the patient, medi-
cations, and osteoporosis risk factors were collected at
baseline and after 9 months of monitoring, via Web-based
survey completed in the pharmacy. Using an intent to
treat approach, the pre–post frequency changes were
compared with contrasts for presence of bisphosphonate
therapy, presence of estrogen therapy, presence of calcium
supplement, discussion of glucocorticoid-induced oste-
oporosis risk, discussion of bone density test, presence
of bone mineral density test, reported inactivity, and
reported low calcium diet.
Results: The contrast was signiﬁcant in favor of the
treatment pharmacies for the frequency of patients tak-
ing a calcium supplement (Control [-6.9%] vs. Treat-
ment [17.1%], P < 0.05). No other contrast was
signiﬁcant.
Conclusions: Community pharmacists are capable of
increasing calcium supplementation among patients at
risk for glucocorticoid-induced osteoporosis. Pharmacists
who educate at-risk patients can impact the self-care of
these patients.
Keywords: glucocorticoid, osteoporosis, pharmacist,
steroid.
 
Introduction
 
The chronic use of glucocorticoids is commonly
employed in the treatment of patients who have
chronic inﬂammatory conditions such as persistent
asthma, rheumatoid arthritis, and inﬂammatory
bowel disease. It has been estimated that more than
one million people in the United States receive long-
term glucocorticoid therapy [1]. Patients who are
on long-term glucocorticoid therapy are at risk for
osteoporosis and fractures [2–11] The adverse effect
of glucocorticoids on bone is most rapid during the
ﬁrst 6 months of therapy and seems to be dose
dependent with doses 
 
≥
 
7.5 mg/day increasing the
patient risk, though even low doses of chronic pred-
nisone therapy can put a patient at potential risk
[12,13]. There are several strategies that clinicians
can use to prevent and treat glucocorticoid-induced
osteoporosis including appropriate monitoring,
instructing patients about dietary and lifestyle
changes, and therapeutic management [14–25].
Unfortunately, although guidelines have been pub-
lished, many patients still do not receive appro-
priate prophylaxis for glucocorticoid-induced
osteoporosis, such as calcium supplementation [26–
28].
Community pharmacists are in an ideal position
to screen and identify patients at risk for osteoporo-
sis [29–31]. Speciﬁcally, community pharmacists
interact regularly with patients and physicians and
can initiate a management process that can reduce
the risk of glucocorticoid-induced osteoporosis. By
communicating with physicians, educating patients,
and providing appropriate monitoring services,
community pharmacists can improve medication
use for patients on long-term glucocorticoid ther-
apy. Given the need for action and the potential
beneﬁt offered by community pharmacists, the goal
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of this project was to utilize a network of pharma-
cists speciﬁcally trained to reduce the risk of
patients on chronic glucocorticoids. The objective
for this study was to assess the impact of pharma-
cists’ risk management activities on patient risk of
glucocorticoid-induced osteoporosis.
 
Risk Factors for Glucocorticoid-Induced 
Osteoporosis
 
There are several risk factors associated with gluco-
corticoid-induced osteoporosis with the dose and
duration of the steroid being a major contributor to
bone loss [32–37]. As mentioned previously, the
most rapid bone loss in patients taking systemic cor-
ticosteroids occurs in the ﬁrst 6 to 12 months of
therapy with estimates of up to 10% to 20% overall
loss of bone mass [3]. The mechanisms by which the
corticosteroids affect bone include decreasing the
intestinal absorption of calcium and phosphate,
increasing urinary calcium excretion, inducing a sec-
ondary hyperparathyroidism, reducing circulating
estrogen and testosterone, and inhibiting osteoblast
proliferation and function [5]. More recent infor-
mation emphasizes the adverse effect that chronic
corticosteroid therapy has on osteoblastic activity
which results in a reduction in bone formation and
a decrease in the ability of bone tissue to repair
itself. More speciﬁcally, chronic glucocorticoid use
may cause an increase in the apotosis of osteoblasts
and osteocytes and suppress the production of new
osteoblasts and osteoclasts [38,39]. Daily doses
greater than or equal to 7.5 mg of predisone or it’s
equivalent appear to cause greater loss of bone com-
pared to lower steroid doses with trabecular bone
being more affected than cortical bone [3,16].
In general, risk factors for osteoporosis include
cigarette smoking, excessive alcohol consumption,
sedentary lifestyle, and hypogonadism. These fac-
tors may further increase an individual’s risk of
glucocorticoid-induced osteoporosis. In addition,
individuals who have a lower baseline bone mineral
density and/or who take medications that are asso-
ciated with secondary causes of bone loss (e.g.,
thyroid hormone, anticonvulsants) are more suscep-
tible to glucocorticoid-induced osteoporosis. Also,
if the individuals who are taking systemic corticos-
teroids have an inadequate calcium and vitamin D
intake they may be more susceptible to bone loss
[3,6,13,16]. Lastly, unlike the other common risk
factors associated with osteoporosis including age,
ethnicity, and sex; these factors have not been asso-
ciated with glucocorticoid-induced osteoporosis
[4,11]. In other words, any individual who initiates
a systemic corticosteroid (
 
≥
 
7.5 mg/day) is at risk of
glucococorticoid-induced osteoporosis regardless of
their age, sex, or ethnic background. Nevertheless,
these factors should be considered because older
postmenopausal women of Caucasian or Asian
decent have a greater risk for the fact that they may
have a lower bone mass when they initiate the cor-
ticosteroid [3].
 
Methods
 
Selection of Pharmacies
 
This study used a randomized control design in
which 15 community pharmacies were randomized
to treatment (n 
 
=
 
 8) or control (n 
 
=
 
 7). Participating
pharmacies are in a network of pharmacies that are
members of Outcomes Pharmaceutical Health
Care®, a specialized provider network. The Out-
comes pharmacies are a diverse set of community
pharmacies, including independent pharmacies and
retail chains. A subset of these pharmacies in east-
ern Iowa has received training and/or certiﬁcation
in monitoring drug therapy and participating in
research projects The pharmacies participating in
this study are located in communities ranging from
less than 2000 to more than 100,000. The number
of pharmacies in the communities ranged from 1 to
38. There were a total of 100 pharmacies in the
communities in which the 15 pharmacies are
located. This indicates that some of the pharmacies
were the only pharmacy providers in their commu-
nities while others were in a highly competitive
environment. Some pharmacies are located within a
clinic, while others are freestanding businesses.
All pharmacists participating in the study
received approximately 4 hours of classroom edu-
cation/training on the pathophysiology and man-
agement of glucocorticoid-induced osteoporosis. In
addition, they were given a packet of articles for
independent study, to which they could refer if they
had further questions regarding prevention and
treatment strategies of glucocorticoid-induced oste-
oporosis. Participation of the Outcomes pharma-
cies was contingent on all pharmacists receiving
the training.
 
Study Design
 
In all pharmacies, patients 18 years of age or older
who had been on the equivalent of at least
7.5 mg of prednisone for at least 6 months were
identiﬁed, using prescription dispensing records.
These patients were believed to be at high risk for
developing osteoporosis. Patients were contacted
through mail by a pharmacist in each practice
and asked to participate. Those who agreed to
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participate signed an informed consent form. The
project was approved by the Human Subjects Com-
mittee at the University of Iowa.
Patients in the control group received usual and
customary care. Patients in the treatment pharma-
cies received education and an educational pam-
phlet about the risks of glucocorticoid-induced
osteoporosis. In addition, the treatment group phar-
macists monitored the patients’ drug therapy, using
Outcomes Encounter Program. The Encounter pro-
gram uses a Web-based claims system that pays
pharmacists to identify and address ﬁve types of
drug-related problems: appropriateness of dose,
proper regimen, potential interactions, nonadher-
ence, and adverse effects. The initial evaluation
focused on the patient’s glucocorticoid therapy and
any medications being used to manage the risks
of developing glucocorticoid-induced osteoporosis.
Subsequent reviews by the pharmacists included
evaluations of drug therapy being studied in addi-
tion to other medications the patients were taking.
Any problems that were identiﬁed were discussed
with the patient and/or the prescribing physician. A
standardized physician communication form was
created and utilized by the treatment pharmacies. A
letter was sent to the physicians who had patients
enrolled in the treatment pharmacies explaining the
program and giving them the opportunity to review
the communication form that the pharmacists
would be sending out to them.
Data were collected at baseline and after
9 months of monitoring, from patients via a Web-
based survey completed in the pharmacy. The sur-
vey collected information about the glucocorticoid
taken by the patient (drug, dose, regimen, and indi-
cation), comorbidities, other medications, and her-
bals. Patients also reported whether or not: anyone
had discussed osteoporosis risk from glucocorti-
coids, anyone had discussed a bone mineral density
test, and they had a bone mineral density test
performed.
The survey also asked patients about speciﬁc risk
factors for osteoporosis. The patients stated the
presence or absence of 10 risk factors for oste-
oporosis: small frame, being female, Caucasian or
Asian, inactivity, low calcium diet, tobacco use,
alcohol consumption, being postmenopausal, a his-
tory of bone fracture, and a family history of oste-
oporosis [40].
 
Data Analysis
 
Frequencies were tabulated for each variable. Chi-
square tests were run to compare frequencies at
baseline between the groups. Also, using intent-to-
treat approach, contrasts compared the difference
between control group baseline and control group
9 month values with the difference between treat-
ment group baseline and treatment group 9 month
values. These variables were: presence of bisphos-
phonate therapy, presence of estrogen therapy,
presence of calcium supplement, discussion of glu-
cocorticoid-induced osteoporosis risk, discussion of
bone density test, presence of bone mineral density
test, reported inactivity, and reported low calcium
diet.
 
Results
 
Ninety-six patients were enrolled (70 treatment, 26
control). Eighty patients completed the study (61
treatment, 19 control). The majority in both groups
were taking the same corticosteroid dose daily at
baseline and 9 months (Table 1). The frequencies
for corticosteroid doses within and between the two
groups did not change signiﬁcantly between base-
line and 9 months. The diagnoses for the use of
the corticosteroids included: chronic obstructive
pulmonary disease (COPD), asthma, rheumatoid
 
Table 1
 
Frequency (%) of  reported risk factors for oste-
oporosis at baseline
 
Risk factor
 
Control
baseline
(n 
 
=
 
 26)
 
Treatment
baseline 
(n 
 
=
 
 70)
 
Small frame 8 (30.8)
 
29 (41.4)
 
Female 15 (57.7)
 
52 (74.3)
 
Caucasian or Asian
descent
24 (92.3)
 
59 (84.3)
 
Inactivity 13 (50) 35 (50)
Low calcium diet 8 (30.8)
 
24 (34.3)
 
Tobacco use (smoker) 6 (23.1)
 
10 (14.3)
Alcohol use*
 
8 (30.8)
 
5 (7.1)
Being postmenopausal*
 
9 (34.6)
 
40 (57.1)
 
History of fracture 3 (11.5) 21 (30)
Family history of
osteoporosis
5 (19.2)
 
12 (17.1)
 
Prednisone average
daily dose
(n 
 
=
 
 20)
 
(n 
 
=
 
 51)
 
Less than 1 mg 0 (0)
 
3 (5.9)
 
1–4 mg 1 (5)
 
3 (5.9)
 
5–9 mg 7 (35)
 
21 (41.2)
 
10–14 mg 7 (35)
 
18 (35.3)
 
15–19 mg 1 (5) 1 (2)
20–29 mg 3 (15)
 
3 (5.9)
 
More than 30 mg 1 (5)
 
2 (3.8)
 
Length of treatment
with corticosteroid
(n 
 
=
 
 24)
 
(n 
 
=
 
 62)
 
Less than 1 years 4 (16.7)
 
5 (8.1)
 
1–2 years 3 (12.5)
 
15 (24.2)
 
3–5 years 7 (29.1)
 
12 (19.3)
 
6–10 years 6 (25)
 
15 (24.2)
 
More than 10 years 4 (16.7)
 
15 (24.2)
 
Mean (SD) number
of medications
5.58 (3.10)
 
7.04 (3.16)
 
*Chi-square signiﬁcant for comparison of  baseline characteristics between groups
at 
 
P
 
 < 0.05.
 Managing Risk of Steroid-Induced Osteoporosis
 
27
 
arthritis, polymyalgia, colitis, Addison’s disease,
Crohn’s disease, cancer, lupus, multiple sclerosis,
vasculitis, and polymyositis.
Also, of the frequencies of reported risk factors
for osteoporosis (small frame, sex, race, inactivity,
low calcium diet, tobacco and alcohol use, post-
menopause, history of fracture, family history) only
alcohol use and postmenopause were different
between the groups (Table 1). There was a signiﬁ-
cant decrease in the frequency of patients reporting
that they were on a low calcium diet within the
treatment group (Table 2).
At baseline, the reported presence of bisphospho-
nate was higher in the treatment group than in the
control group. The treatment group showed a sig-
niﬁcant change between baseline and 9 months for
the addition of bisphosphonate, estrogen, and/or
the addition of calcium supplementation (Table 3).
Contrasts comparing the change in frequencies
between the groups showed a signiﬁcant difference
in the change only for the presence of a calcium sup-
plement. The treatment group had a signiﬁcant
increase in the number of patients who had started
on a calcium supplement, compared to the change
in the control group.
The frequency of discussion of glucocorticoid-
induced osteoporosis risk between the pharmacist
and the patient did increase signiﬁcantly in the
treatment group from baseline, although the
change was not signiﬁcant when contrasting the
change between the two groups. Similarly, the
patient’s awareness of a test to measure bone min-
eral density increased in the treatment group,
although it was trending upward for the control
group and the change between groups was not sig-
niﬁcant. Lastly, both groups demonstrated an
increase in the frequency of patients who reported
that they had a bone density test performed,
although the change was not signiﬁcant between
the groups (Table 4).
 
Table 2
 
Frequency (%) of  modiﬁable risk factors at baseline and 9 months
 
Control baseline
(n 
 
=
 
 26)
Control 9 months
(n 
 
=
 
 19)
Treatment baseline
(n 
 
=
 
 70)
Treatment 9 months 
(n 
 
=
 
 61)
Inactivity 13 (50) 7 (36.8) 35 (50) 24 (39.3)
Low calcium diet 8 (30.8) 3 (15.8) 24 (34.3) 11 (18)
 
†
 
Tobacco use (smoker) 6 (23.1) 3 (15.8) 10 (14.3) 8 (13.1)
Alcohol use* 8 (30.8) 4 (21.1) 5 (7.1) 7 (11.5)
 
*Chi-square signiﬁcant for comparison of  baseline characteristics between groups at 
 
P
 
 < 0.05.
 
†
 
Chi-square signiﬁcant for comparison of  baseline and 9 months within group at 
 
P
 
 < 0.05.
 
Table 3
 
Frequency (%) of  presence of  therapy
 
Control baseline
(n 
 
=
 
 26)
Control 9 months
(n 
 
=
 
 19)
Treatment baseline
(n 
 
=
 
 70)
Treatment 9 months 
(n 
 
=
 
 61)
Bisphosphonate therapy* 0 (0.0) 2 (10.5) 12 (17.1) 16 (26.2)
 
†
 
Estrogen therapy 0 (0.0) 0 (0.0) 9 (12.9) 10 (16.4)
 
†
 
Calcium supplement 10 (38.5) 6 (31.6) 27 (38.6) 34 (55.7)
 
†,‡
 
*Chi-square signiﬁcant for comparison of  baseline characteristics between groups at P < 0.05.
 
†
 
Chi-square signiﬁcant for comparison of  baseline and 9 months within group at P < 0.05.
 
‡
 
Contrast comparing change in control to change in treatment groups signiﬁcant (P < 0.05).
 
Table 4
 
Frequency (%) bone density test awareness and testing
 
Control baseline
(n 
 
=
 
 26)
Control 9 months
(n 
 
=
 
 19)
Treatment baseline*
(n 
 
=
 
 69)
Treatment 9 months 
(n 
 
=
 
 57)
Aware of  bone density test 21 (80.8) 18 (94.7) 52 (75.4) 54 (94.7)
 
‡
 
Reported bone density test performed
 
†
 
6 (24) 12 (63.2)
 
‡
 
34 (52.3) 41 (71.9)
 
‡
 
*There were only 65 usable responses for reported bone density test performed at baseline.
 
†
 
Chi-square signiﬁcant for comparison of  baseline characteristics between groups at 
 
P
 
 < 0.05.
 
‡
 
Chi-square signiﬁcant for comparison of  baseline and 9 months within group at 
 
P
 
 < 0.05.
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Using the Encounter program, pharmacists in
the treatment arm were able to identify and make
recommendations on 16-drug therapy problems
related to glucocorticoid-induced osteoporosis. Of
these 16 problems, 6 addressed the risk of pred-
nisone related adverse drug reactions. Seven of the
identiﬁed problems recommended changing the
dose or type of calcium supplement to improve
therapy. Other identiﬁed drug therapy problems
included issues of adherence and duplicate therapy.
 
Discussion
 
Effect on Risk Management Activities
 
The patients who were enrolled in the study had
other risk factors for osteoporosis in addition to
their glucocorticoid use. It is not surprising that the
nonmodiﬁable risk factors (small frame, sex, race,
postmenopausal, history of fracture, and family
history) remained unchanged from baseline to
9 months between and within groups. Nevertheless,
two of the modiﬁable risk factors, inactivity and
low calcium diet, had a downward trend from base-
line to 9 months for both groups. The decrease in
frequency of reported low calcium diet was signiﬁ-
cant for the treatment group, but not for the control
group. This change is not surprising given that the
treatment group reported a signiﬁcant increase in
calcium supplementation as compared to the con-
trol group.
The treatment group had a signiﬁcant increase in
the frequency of patients who were started on
bisphosphonates, estrogen, and calcium supple-
ments. In addition, 44% of the pharmacist inter-
ventions focused on calcium. When the pre–post
frequency changes were compared between the
groups, the contrasts were signiﬁcant only for the
frequency of patients who are taking a calcium
supplement. This means that a sizable increase
occurred in the control group for presence of
bisphosphonate and for presence of estrogen. One
explanation for this result is that pharmacists in
both groups were given comprehensive education
and training in glucocorticoid-induced osteoporo-
sis, and as members of the Outcomes® network,
they had received extensive training in therapeutics
and skill development. During the project training,
treatment and control pharmacists were instructed
on the importance of baseline testing of bone min-
eral density and the importance of medications and
calcium supplements for treatment and prevention
of osteoporosis. This training may have caused the
control pharmacists to make a therapeutic interven-
tion, resulting in the increases for bisphosphonate
and estrogen in the control group. In addition, the
increase in the presence of bisphosphonate therapy
in both groups could have been stimulated in part
by the marketing activities of the manufacturers of
bisphosphonates.
The patients who went to the treatment pharma-
cies received an educational session about the risks
of glucocorticoid-induced osteoporosis. As part of
the education, they received an educational pam-
phlet that emphasized the importance of calcium
supplementation. This combination of education by
a pharmacist and written information appeared to
be effective in inﬂuencing patients to take a calcium
supplement. In addition, the pharmacists addressed
calcium supplements in some of their Encounter
services. Together, the education and monitoring
raised patients’ reported use of calcium
supplements.
Because glucocorticoid-induced osteoporosis
results in a negative calcium balance, it is important
that individuals who are started on long-term sys-
temic corticosteroid therapy begin monitoring their
calcium and vitamin D intake [3,5,6]. Current
guidelines recommend that patients maintain a
daily calcium intake of 1500 mg/day along with
800 IU of vitamin D, unless contraindicated [12].
This simple intervention will help to normalize the
calcium balance which was adversely affected by
the corticosteroid. Furthermore, by restoring the
calcium balance this may limit the amount of bone
loss experienced by the individual. This was further
emphasized in a study looking at daily calcium
and vitamin D supplementation in patients taking
chronic low doses of prednisone (average of 5.6 mg/
day). The supplementation prevented loss of bone
mineral density in the lumbar spine and trochanter
in patients using chronic prednisone therapy for
rheumatoid arthritis [41]. Although calcium and
vitamin D supplementation is an important inter-
vention, it is usually not enough to reduce the risk
of bone loss associated with systemic corticoster-
oids. Most patients will need additional agents such
as bisphosphonates to provide them with adequate
protection from additional bone loss [3,5,13].
 
Identifying Patients at Risk for Glucocorticoid-Induced 
Osteoporosis
 
Through examination of their patient records (e.g.,
dispensing proﬁles), community pharmacists were
able to identify patients who were taking sufﬁcient
amounts of glucocorticoids to put them at risk of
glucocorticoid-induced osteoporosis. This required
performing some reports using the computers and
then some computations by the pharmacists. It
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appears that such a risk screening process could be
more widely used in community pharmacies. These
patients then could be contacted about managing
their risks.
In addition to the glucocorticoid identiﬁed from
the dispensing records, 10 risk factors were assessed
with a web-based survey completed by the patients
in the pharmacies. Some of the risk factors are not
modiﬁable (e.g., sex), while others potentially could
be changed (e.g., low calcium diet, activity levels,
smoking, and alcohol consumption). Further work
should be done to develop interventions that can
positively change the mutable risk factors.
 
Limitations
 
A limitation of this study was the low number of
patients that were enrolled in the control group. It
was up to the pharmacists to recruit patients. Some
sites did a better job of recruiting, retaining, and fol-
lowing up with subjects in the project. Another
explanation for the lower number in the control
group may be that the control pharmacies were less
committed to the project because they provided
usual and customary services and had less contact
with the patients compared to the treatment
pharmacies.
Power for this study was low because of a lower
recruitment of patients than what was expected.
There were 163 potential patients that were origi-
nally identiﬁed by the participating pharmacies, but
only 96 were recruited. Because of this low power,
we were less able to detect signiﬁcant differences.
Another limitation of this study is that the con-
trol and treatment patients differed somewhat at
baseline. For example, fewer members of the treat-
ment group reported using alcohol, but more
reported being postmenopausal. These differences
make it difﬁcult to assess a change between the
groups. To address this limitation, contrasts were
used to compare changes within groups.
Another limitation is that the pharmacists in
both groups were educated regarding the risks of
glucocorticoid-induced osteoporosis and the pre-
vention and treatment strategies used to reduce the
risks. Also, each of the 15 sites, both treatment
and control pharmacies, had participated in other
research projects and had been trained in monitor-
ing drug therapies. This may explain why the dif-
ferences between the treatment pharmacies and the
control pharmacies were not as great as expected.
We believe that the results understate the impact
that a patient monitoring and education interven-
tion could have in most community pharmacies.
Future studies could assess pharmacists who have
been trained versus a peer group that has not had
the same educational interventions.
Additionally, the relatively low number of phar-
macist Encounter interventions is a limitation of
this study. While it is difﬁcult to precisely explain
why the level was low, there are a number of pos-
sible explanations. First, only recommendations
accepted by a physician were included in the
Encounter claims, suggesting that differences in
clinical judgment between the pharmacist and phy-
sicians may have limited the number of accepted
recommendations.
Also, the treatment pharmacies may have lacked
sufﬁcient capacity to provide a high volume of mon-
itoring services. Although these pharmacies are pro-
viding new pharmacy services, they are building
their service capacity gradually. Thus, the pharma-
cies in the treatment group may not have commu-
nicated with the subjects sufﬁciently to change risk
factors such as taking bisphosphonate therapy. Data
were not collected on the number of times the phar-
macists interacted with the subjects regarding
managing their risks of glucocorticoid-induced
osteoporosis.
 
Conclusions
 
Community pharmacists are capable of increasing
calcium supplementation among patients at risk
for glucocorticoid-induced osteoporosis. Pharma-
cists who educate at-risk patients and communi-
cate with physicians can impact the management
of these patients, especially self-management (e.g.,
taking calcium supplements). Patients who are
counseled by pharmacists have an increased aware-
ness of their risk, are more aware of the need for
bone mineral density testing, and are started on
therapeutic agents to manage their risk. In particu-
lar, pharmacists who counsel patients and provide
them with written materials can impact patient’s
understanding for the importance of their
therapies.
 
Source of ﬁnancial support: This study was supported by
an unrestricted educational grant from Merck and Co.,
Inc. and by the Center for Improving Medication Use in
the Community at the University of Iowa.
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